Lexaria Bioscience (LEXX) Payables (2011 - 2026)
Lexaria Bioscience (LEXX) posted Payables of $350377.0 for Q2 2026, up 91.87% sequentially from $182611.0 in Q1 2026, and down 75.97% YoY from $1.5 million in Q2 2025.
Lexaria Bioscience (LEXX) Payables (2011 - 2026) Analysis & Trends
Lexaria Bioscience has reported Payables for 16 years, with the latest figure at $350377.0 in Q2 2026.
- Quarterly Payables fell 75.97% year-over-year to $350377.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $350377.0 (down 75.97% YoY) and the FY2025 annual result came in at $1.5 million, up 37.19% from the prior year.
- Payables grew to $350377.0 in Q2 2026 per LEXX's latest filing, from $182611.0 in the prior quarter.
- Over five years, Payables peaked at $1.8 million in Q1 2025 and troughed at $55318.0 in Q1 2024.
- A 5-year average of $578422.6 and a median of $240916.0 in 2022 frame the typical range for Payables.
- The sharpest annual moves came in 2025 and 2026: Payables jumped 3141.4% in 2025, then sank 89.82% in 2026.
- Over 5 years, Payables stood at $241891.0 in 2022, then tumbled by 59.09% to $98969.0 in 2023, then surged by 171.79% to $268986.0 in 2024, then jumped by 429.93% to $1.4 million in 2025, then sank by 75.42% to $350377.0 in 2026.
- According to Business Quant data, Payables over the past three periods registered $350377.0, $182611.0, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 350,377.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 350,377.00 |
| Feb 28, 2026 | 182,611.00 |
| Nov 30, 2025 | 1.43 Mn |
| Aug 31, 2025 | 1.46 Mn |
| May 31, 2025 | 1.46 Mn |
| Feb 28, 2025 | 1.79 Mn |
| Nov 30, 2024 | 268,986.00 |
| Aug 31, 2024 | 1.07 Mn |
| May 31, 2024 | 128,788.00 |
| Feb 29, 2024 | 55,318.00 |
| Nov 30, 2023 | 98,969.00 |
| Aug 31, 2023 | 239,941.00 |
| May 31, 2023 | 1.02 Mn |
| Feb 28, 2023 | 189,776.00 |
| Nov 30, 2022 | 241,891.00 |
| Aug 31, 2022 | 151,449.00 |
| May 31, 2022 | 157,095.00 |
| Feb 28, 2022 | 116,592.00 |
| Nov 30, 2021 | 189,542.00 |
| Aug 31, 2021 | 105,946.00 |